However, there are discrepant observations on nuclear versus cytoplasmic localization of AEG-1 in metastatic CRC cells further stressing the necessity of using a standard IHC protocol with a clinically approved AEG-1 antibody. This evidence concerns the gene MTDH and colorectal carcinoma.